W Frank Peacock1, Brigette M Baumann2, Deborah Bruton3, Thomas E Davis4, Beverly Handy5, Christopher W Jones2, Judd E Hollander6, Alexander T Limkakeng7, Abhi Mehrotra8, Martin Than9, Andre Ziegler10, Carina Dinkel11. 1. Emergency Medicine, Baylor College of Medicine, Houston, Texas. 2. Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, New Jersey. 3. Roche Diagnostics Operations, Indianapolis, Indiana. 4. Indiana University School of Medicine, Indianapolis. 5. Department of Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston. 6. Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania. 7. Division of Emergency Medicine, Duke University, Durham, North Carolina. 8. Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill. 9. Emergency Department, Christchurch Hospital, Christchurch, New Zealand. 10. Roche Diagnostics International, Rotkreuz, Switzerland. 11. Roche Diagnostics GmbH, Penzberg, Germany.
Abstract
Importance: Physicians need information on how to use the first available high-sensitivity troponin (hsTnT) assay in the United States to identify patients at very low risk for 30-day adverse cardiac events (ACE). Objective: To determine whether a negative hsTnT assay at 0 and 3 hours following emergency department presentation could identify patients at less than 1% risk of a 30-day ACE. Design, Setting, and Participants: A prospective, observational study at 15 emergency departments in the United States between 2011 and 2015 that included individuals 21 years and older, presenting to the emergency department with suspected acute coronary syndrome. Of 1690 eligible individuals, 15 (no cardiac troponin T measurement) and 320 (missing a 0-hour or 3-hour sample) were excluded from the analyses. Exposures: Serial hsTnT measurements (fifth-generation Roche Elecsys hsTnT assay). Main Outcomes and Measures: Serial blood samples from each patient were collected after emergency department presentation (once identified as a potential patient with acute coronary syndrome) and 3 hours, 6 to 9 hours, and 12 to 24 hours later. Adverse cardiac events were defined as myocardial infarction, urgent revascularization, or death. The upper reference level for the hsTnT assay, defined as the 99th percentile, was established as 19 ng/L in a separate healthy US cohort. Patients were considered ruled out for acute myocardial infarction if their hsTnT level at 0 hours and 3 hours was less than the upper reference level. Gold standard diagnoses were determined by a clinical end point committee. Evaluation of assay clinical performance for acute myocardial infarction rule-out was prespecified; the hypothesis regarding 30-day ACE was formulated after data collection. Results: In 1301 healthy volunteers (50.4% women; median age, 48 years), the upper reference level was 19 ng/L. In 1600 patients with suspected acute coronary syndrome (48.4% women; median age, 55 years), a single hsTnTlevel less than 6 ng/L at baseline had a negative predictive value for AMI of 99.4%. In 974 patients (77.1%) with both 0-hour and 3-hour hsTnT levels of 19 ng/L or less, the negative predictive value for 30-day ACE was 99.3% (95% CI, 99.1-99.6). Using sex-specific cutpoints, C statistics for women (0.952) and men (0.962) were similar for acute myocardial infarction. Conclusions and Relevance: A single hsTnT level less than 6 ng/L was associated with a markedly decreased risk of AMI, while serial levels at 19 ng/L or less identified patients at less than 1% risk of 30-day ACE.
Importance: Physicians need information on how to use the first available high-sensitivity troponin (hsTnT) assay in the United States to identify patients at very low risk for 30-day adverse cardiac events (ACE). Objective: To determine whether a negative hsTnT assay at 0 and 3 hours following emergency department presentation could identify patients at less than 1% risk of a 30-day ACE. Design, Setting, and Participants: A prospective, observational study at 15 emergency departments in the United States between 2011 and 2015 that included individuals 21 years and older, presenting to the emergency department with suspected acute coronary syndrome. Of 1690 eligible individuals, 15 (no cardiac troponin T measurement) and 320 (missing a 0-hour or 3-hour sample) were excluded from the analyses. Exposures: Serial hsTnT measurements (fifth-generation Roche Elecsys hsTnT assay). Main Outcomes and Measures: Serial blood samples from each patient were collected after emergency department presentation (once identified as a potential patient with acute coronary syndrome) and 3 hours, 6 to 9 hours, and 12 to 24 hours later. Adverse cardiac events were defined as myocardial infarction, urgent revascularization, or death. The upper reference level for the hsTnT assay, defined as the 99th percentile, was established as 19 ng/L in a separate healthy US cohort. Patients were considered ruled out for acute myocardial infarction if their hsTnT level at 0 hours and 3 hours was less than the upper reference level. Gold standard diagnoses were determined by a clinical end point committee. Evaluation of assay clinical performance for acute myocardial infarction rule-out was prespecified; the hypothesis regarding 30-day ACE was formulated after data collection. Results: In 1301 healthy volunteers (50.4% women; median age, 48 years), the upper reference level was 19 ng/L. In 1600 patients with suspected acute coronary syndrome (48.4% women; median age, 55 years), a single hsTnTlevel less than 6 ng/L at baseline had a negative predictive value for AMI of 99.4%. In 974 patients (77.1%) with both 0-hour and 3-hour hsTnT levels of 19 ng/L or less, the negative predictive value for 30-day ACE was 99.3% (95% CI, 99.1-99.6). Using sex-specific cutpoints, C statistics for women (0.952) and men (0.962) were similar for acute myocardial infarction. Conclusions and Relevance: A single hsTnT level less than 6 ng/L was associated with a markedly decreased risk of AMI, while serial levels at 19 ng/L or less identified patients at less than 1% risk of 30-day ACE.
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Circulation Date: 2012-08-24 Impact factor: 29.690
Authors: Fred S Apple; Allan S Jaffe; Paul Collinson; Martin Mockel; Jordi Ordonez-Llanos; Bertil Lindahl; Judd Hollander; Mario Plebani; Martin Than; M H M Chan Journal: Clin Biochem Date: 2014-09-07 Impact factor: 3.281
Authors: Michael J Lipinski; Nevin C Baker; Ricardo O Escárcega; Rebecca Torguson; Fang Chen; Sally J Aldous; Michael Christ; Paul O Collinson; Steve W Goodacre; Johannes Mair; Kenji Inoue; Ulrich Lotze; Mustapha Sebbane; Jean-Paul Cristol; Yonathan Freund; Camille Chenevier-Gobeaux; Christophe Meune; Kai M Eggers; Radosław Pracoń; Donald H Schreiber; Alan H B Wu; Jordi Ordoñez-Llanos; Allan S Jaffe; Raphael Twerenbold; Christian Mueller; Ron Waksman Journal: Am Heart J Date: 2014-10-22 Impact factor: 4.749
Authors: Jesse M Pines; Charles V Pollack; Deborah B Diercks; Anna Marie Chang; Frances S Shofer; Judd E Hollander Journal: Acad Emerg Med Date: 2009-06-22 Impact factor: 3.451
Authors: Steven L Bernstein; Dominik Aronsky; Reena Duseja; Stephen Epstein; Dan Handel; Ula Hwang; Melissa McCarthy; K John McConnell; Jesse M Pines; Niels Rathlev; Robert Schafermeyer; Frank Zwemer; Michael Schull; Brent R Asplin Journal: Acad Emerg Med Date: 2008-11-08 Impact factor: 3.451
Authors: Anoop S V Shah; Megan Griffiths; Kuan Ken Lee; David A McAllister; Amanda L Hunter; Amy V Ferry; Anne Cruikshank; Alan Reid; Mary Stoddart; Fiona Strachan; Simon Walker; Paul O Collinson; Fred S Apple; Alasdair J Gray; Keith A A Fox; David E Newby; Nicholas L Mills Journal: BMJ Date: 2015-01-21
Authors: Peter A Kavsak; Joshua O Cerasuolo; Dennis T Ko; Jinhui Ma; Jonathan Sherbino; Shawn E Mondoux; Natasha Clayton; Stephen A Hill; Matthew McQueen; Lauren E Griffith; Shamir R Mehta; Richard Perez; Hsien Seow; P J Devereaux; Andrew Worster Journal: CMAJ Open Date: 2020-11-02
Authors: Carol L Clark; Thomas A Gibson; Robert E Weiss; Annick N Yagapen; Susan E Malveau; David H Adler; Aveh Bastani; Christopher W Baugh; Jeffrey M Caterino; Deborah B Diercks; Judd E Hollander; Bret A Nicks; Daniel K Nishijima; Manish N Shah; Kirk A Stiffler; Alan B Storrow; Scott T Wilber; Benjamin C Sun Journal: Acad Emerg Med Date: 2019-03-04 Impact factor: 3.451
Authors: Yader Sandoval; Bradley R Lewis; Ramila A Mehta; Olatunde Ola; Jonathan D Knott; Laura De Michieli; Ashok Akula; Ronstan Lobo; Eric H Yang; S Michael Gharacholou; Marshall Dworak; Erika Crockford; Nicholas Rastas; Eric Grube; Swetha Karturi; Scott Wohlrab; David O Hodge; Tahir Tak; Charles Cagin; Rajiv Gulati; Allan S Jaffe Journal: Circulation Date: 2022-05-10 Impact factor: 39.918
Authors: Nicholas J Bevins; Hyojin Chae; Jacqueline A Hubbard; Edward M Castillo; Vaishal M Tolia; Lori B Daniels; Robert L Fitzgerald Journal: Am J Clin Pathol Date: 2022-05-04 Impact factor: 5.400
Authors: Xinmin S Li; Slayman Obeid; Zeneng Wang; Benjamin J Hazen; Lin Li; Yuping Wu; Alex G Hurd; Xiaodong Gu; Alan Pratt; Bruce S Levison; Yoon-Mi Chung; Steven E Nissen; Wai Hong Wilson Tang; François Mach; Lorenz Räber; David Nanchen; Christian M Matter; Thomas F Lüscher; Stanley L Hazen Journal: Eur Heart J Date: 2019-08-21 Impact factor: 29.983
Authors: Júlia Karády; Thomas Mayrhofer; Maros Ferencik; John T Nagurney; James E Udelson; Andreas A Kammerlander; Jerome L Fleg; W Frank Peacock; James L Januzzi; Wolfgang Koenig; Udo Hoffmann Journal: J Am Coll Cardiol Date: 2021-03-30 Impact factor: 24.094
Authors: Philip W Chui; Denise Esserman; Lori A Bastian; Jeptha P Curtis; Parul U Gandhi; Lindsey Rosman; Nihar Desai; Ronald G Hauser Journal: Med Care Date: 2020-12 Impact factor: 3.178